Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.

Kearns JT, Holt SK, Wright JL, Lin DW, Lange PH, Gore JL.

Cancer. 2018 Jul 1;124(13):2733-2739. doi: 10.1002/cncr.31337. Epub 2018 May 21.

2.

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E.

Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3.

3.

Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.

Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227. doi: 10.1158/1055-9965.EPI-16-0434. Epub 2016 Oct 14.

4.

Re: Intermittent Androgen Deprivation (IAD) in Prostate Cancer (PC): Are We Ready To Quit?

Lange PH.

Eur Urol. 2016 Sep;70(3):542-3. doi: 10.1016/j.eururo.2016.06.028. Epub 2016 Jul 4. No abstract available.

PMID:
27387125
5.

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 May;14(5):509-19.

PMID:
27160230
6.

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C.

Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16.

7.

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS.

Nat Med. 2016 Apr;22(4):369-78. doi: 10.1038/nm.4053. Epub 2016 Feb 29.

8.

Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.

Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam HM, Brown LG, Ketchanji M, Nghiem B, Lakely B, Coleman R, Montgomery B, Lange PH, Roudier M, Higano CS, Bielas JH, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2016 Mar;33(3):239-48. doi: 10.1007/s10585-015-9773-7. Epub 2015 Dec 14.

9.

NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D.

J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61.

PMID:
26656522
10.

High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.

Wu Y, Schoenborn JR, Morrissey C, Xia J, Larson S, Brown LG, Qu X, Lange PH, Nelson PS, Vessella RL, Fang M.

J Mol Diagn. 2016 Jan;18(1):131-43. doi: 10.1016/j.jmoldx.2015.08.004. Epub 2015 Nov 20.

11.

The biology and clinical implications of prostate cancer dormancy and metastasis.

Morrissey C, Vessella RL, Lange PH, Lam HM.

J Mol Med (Berl). 2016 Mar;94(3):259-65. doi: 10.1007/s00109-015-1353-4. Epub 2015 Oct 21. Review.

12.

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C.

Clin Cancer Res. 2015 Oct 15;21(20):4698-708. doi: 10.1158/1078-0432.CCR-15-0157. Epub 2015 Jun 12.

13.

Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.

Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS.

PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014.

14.

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219.

PMID:
25190691
15.

Maximal testosterone suppression in prostate cancer--free vs total testosterone.

Rove KO, Crawford ED, Perachino M, Morote J, Klotz L, Lange PH, Andriole GL, Matsumoto AM, Taneja SS, Eisenberger MA, Reis LO.

Urology. 2014 Jun;83(6):1217-22. doi: 10.1016/j.urology.2014.02.001. Epub 2014 Apr 6. Review.

16.

Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.

Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL.

Am J Surg Pathol. 2014 Mar;38(3):333-8. doi: 10.1097/PAS.0000000000000162.

17.

Dormancy in solid tumors: implications for prostate cancer.

Ruppender NS, Morrissey C, Lange PH, Vessella RL.

Cancer Metastasis Rev. 2013 Dec;32(3-4):501-9. doi: 10.1007/s10555-013-9422-z. Review.

18.

Single cell transcriptomic analysis of prostate cancer cells.

Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL, Morrissey C.

BMC Mol Biol. 2013 Feb 16;14:6. doi: 10.1186/1471-2199-14-6.

19.

Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.

Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C.

Prostate. 2013 Jun;73(9):932-40. doi: 10.1002/pros.22639. Epub 2013 Jan 17.

20.
21.

Penile carcinoma: lessons learned from vulvar carcinoma.

Longpre MJ, Lange PH, Kwon JS, Black PC.

J Urol. 2013 Jan;189(1):17-24. doi: 10.1016/j.juro.2012.08.082. Epub 2012 Nov 16. Review.

PMID:
23158472
22.

Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series.

Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL.

J Bone Miner Res. 2013 Feb;28(2):333-40. doi: 10.1002/jbmr.1749.

23.

Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient.

Penson DF, Lange PH.

Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S2-4. doi: 10.1016/j.urolonc.2011.04.008. Review.

PMID:
22795076
24.

Legends in urology.

Lange PH.

Can J Urol. 2012 Jun;19(3):6240-2. No abstract available.

25.

Editorial comment.

Lange PH.

Urology. 2011 Nov;78(5):992; author reply 993. doi: 10.1016/j.urology.2011.07.1407. No abstract available.

PMID:
22054362
26.

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.

Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17087-92. doi: 10.1073/pnas.1108745108. Epub 2011 Sep 26.

28.

Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality.

Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, Lin DW.

J Urol. 2010 Jun;183(6):2213-8. doi: 10.1016/j.juro.2010.02.017.

29.

Editorial comment.

Lange PH.

Urology. 2010 Feb;75(2):405; author reply 405-6. doi: 10.1016/j.urology.2009.09.030. No abstract available.

PMID:
20152494
30.

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM.

Cancer. 2010 Apr 1;116(7):1699-708. doi: 10.1002/cncr.24960.

31.

NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT.

J Natl Compr Canc Netw. 2010 Feb;8(2):240-62. No abstract available.

PMID:
20141680
32.

NCCN clinical practice guidelines in oncology: prostate cancer.

Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC.

J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. No abstract available.

PMID:
20141676
33.
34.

NCCN clinical practice guidelines in oncology: kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. No abstract available.

PMID:
19555584
35.

NCCN clinical practice guidelines in oncology: testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):672-93. No abstract available.

PMID:
19555582
36.

Prostate cancer-associated gene expression alterations determined from needle biopsies.

Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM.

Clin Cancer Res. 2009 May 1;15(9):3135-42. doi: 10.1158/1078-0432.CCR-08-1982. Epub 2009 Apr 14.

37.

The future of urologic oncology: "Proceduralists" or continued leaders?

Lange PH.

Urol Oncol. 2009 Mar-Apr;27(2):118-9. doi: 10.1016/j.urolonc.2008.10.009. No abstract available.

PMID:
19285218
38.

Bladder cancer.

Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Jan;7(1):8-39. No abstract available.

PMID:
19176203
39.

Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.

Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL.

Clin Cancer Res. 2009 Jan 15;15(2):677-83. doi: 10.1158/1078-0432.CCR-08-1754.

40.

Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.

Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL.

Cancer Res. 2008 Jul 15;68(14):5599-608. doi: 10.1158/0008-5472.CAN-08-0812.

41.

Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.

Lange PH.

Eur Urol. 2009 Mar;55(3):609. doi: 10.1016/j.eururo.2008.06.046. Epub 2008 Jun 23. No abstract available.

PMID:
18597925
42.

The future of urological oncology: proceduralists or continued primary physicians and leaders.

Lange PH.

J Urol. 2008 Jun;179(6):2085-6. doi: 10.1016/j.juro.2008.03.123. No abstract available.

PMID:
18423757
43.

Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.

Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Lin DW.

J Urol. 2008 May;179(5):1775-9. doi: 10.1016/j.juro.2008.01.016. Epub 2008 Mar 17.

PMID:
18343432
44.

WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.

Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA.

Clin Cancer Res. 2008 Mar 1;14(5):1397-406. doi: 10.1158/1078-0432.CCR-07-1535.

45.

Newer potential biomarkers in prostate cancer.

Wright JL, Lange PH.

Rev Urol. 2007 Fall;9(4):207-13.

46.

Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.

Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL.

Clin Exp Metastasis. 2008;25(4):377-88. Epub 2007 Oct 31.

PMID:
17972146
47.
48.

Prostate cancer early detection. Clinical practice guidelines in oncology.

Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet GP 3rd, Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Patterson S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2007 Aug;5(7):714-36. No abstract available.

PMID:
17692177
49.

Point: open radical prostatectomy should not be abandoned.

Ellis WJ, Lange PH.

J Natl Compr Canc Netw. 2007 Aug;5(7):685-8. Review.

PMID:
17692171
50.

Prostate cancer. Clinical practice guidelines in oncology.

Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC; National Comprehensive Cancer Nerwork.

J Natl Compr Canc Netw. 2007 Aug;5(7):650-83. No abstract available.

PMID:
17692170

Supplemental Content

Loading ...
Support Center